CATALOGO DEI PRODOTTI DELLA RICERCA

The Breast DX Italy prospective study evaluated the impact of the 21-gene recurrence score (RS) result on adjuvant treatment decisions for patients with early breast cancer.

First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer

Guarneri, Valentina;Tortora, Giampaolo;Pasini, Felice;Conte, Pierfranco
2017-01-01

Abstract

The Breast DX Italy prospective study evaluated the impact of the 21-gene recurrence score (RS) result on adjuvant treatment decisions for patients with early breast cancer.
2017
Inglese
STAMPA
Sì, ma tipo non specificato
THE ONCOLOGIST
N/D
N/D
N/D
29133514
WOS:000427020800006
2-s2.0-85038222866
https://dx.doi.org/10.1634/theoncologist.2017-0322
Adjuvant chemotherapy; Early breast cancer; Estrogen receptor positive; Recurrence score; Treatment change
none
info:eu-repo/semantics/article
Dieci, Maria Vittoria; Guarneri, Valentina; Giarratano, Tommaso; Mion, Marta; Tortora, Giampaolo; De Rossi, Costanza; Gori, Stefania; Oliani, Cristina...espandi
18
01 Contributo in rivista::01.01 Articolo in Rivista
262
01.01 Articolo in Rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/975333
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 11
social impact